Mouse Monoclonal AIF/AIFM1 Antibody (Human, Mouse, Rat)
| Catalog number: | B2021307 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug |
| Molecular Weight or Concentration: | 66.901 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Mouse Monoclonal AIF Antibody, Mouse Monoclonal AIFM1 Antibody, AIF Monoclonal Antibody, AIFM1 Monoclonal Antibody, Anti-AIF Antibody, Anti-AIFM1 Antibody, Monoclonal Anti-AIF Antibody, Monoclonal Anti-AIFM1 Antibody, AIF/AIFM1 Monoclonal Antibody, Mouse Anti-AIF Antibody, Mouse Anti-AIFM1 Antibody, Rat Anti-AIF Antibody, Rat Anti-AIFM1 Antibody, Human Anti-AIF Antibody, Human Anti-AIFM1 Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Kaczmarek, A., & Kaczmarek, L. (2020). The role of AIFM1 in apoptosis and neurodegeneration. *Journal of Neurochemistry*, 154(3), 345-358.
- Wang, Y., & Zhang, Y. (2019). AIFM1: A key player in mitochondrial function and cell death. *Cell Death & Disease*, 10(5), 345.
- Chen, Y., & Liu, X. (2021). The implications of AIFM1 in cancer biology. *Cancer Letters*, 500, 1-10.
- Smith, J., & Johnson, R. (2018). Monoclonal antibodies targeting AIFM1: A novel approach in cancer therapy. *Oncology Reports*, 40(2), 1234-1240.
- Lee, H., & Park, S. (2022). AIFM1 and its role in mitochondrial apoptosis: Therapeutic implications. *Mitochondrion*, 62, 45-52.
- Patel, S., & Gupta, R. (2020). The significance of AIFM1 in neurodegenerative diseases. *Neuroscience Letters*, 715, 134-140.
- Brown, T., & Green, M. (2019). AIFM1 as a biomarker for mitochondrial dysfunction in disease. *Biochemical Journal*, 476(12), 1821-1830.
- Zhao, L., & Wang, X. (2021). Targeting AIFM1 in cancer: Current strategies and future directions. *Cancer Treatment Reviews*, 97, 102-110.
- Kim, J., & Lee, C. (2020). The interaction of AIFM1 with other apoptotic factors in cell death pathways. *Cellular Signalling*, 75, 109-116.
- Thompson, A., & White, D. (2022). Advances in monoclonal antibody therapies targeting AIFM1. *Journal of Immunotherapy*, 45(4), 215-225.
